Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Nikon Bets 10 Billion Yen on Regenerative Medicine CDMO Push
Nikon CeLL Innovation (NCLi) will pour more than 10 billion yen over the next three years into expanding its regenerative medicine CDMO business, bolstering facilities and technologies for products derived from CAR-T cells, iPS cells, and mesenchymal stem cells (MSCs).…
To read the full story
Related Article
- BMS, Nikon Pitch Japan-to-Asia Cell Therapy Push, Draw Support at Policy Forum
May 21, 2026
- BMS Files to Fully Localize Breyanzi Production in Japan
April 8, 2026
- BMS, Nikon Eye Full Domestic CAR-T Manufacturing in Japan from 2027
March 19, 2026
- Keio Spinoff Taps Nikon as CDMO, Targets 2027 Start for KP8011 Trial
February 25, 2026
- BMS Mulls CAR-T Manufacturing in Japan, Definitive Plans Expected by Year-End
February 14, 2023
BUSINESS
- Lilly Confirms Orforglipron Diabetes Filings in US, Japan
August 7, 2026
- Takeda Snares US Approval for Orzeyful in Narcolepsy Type 1
August 7, 2026
- Inrebic Expands First-Line Treatment Options for Myelofibrosis: Expert
August 7, 2026
- Meiji Pharma Drops Hiyasta Development in B-Cell NHL
August 7, 2026
- AstraZeneca Japan Chief Says MFN Response Requires Drug Pricing Reform
August 5, 2026
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…